News Conference News ACC 2025 By 2 Years, Tricuspid TEER Reduces Hospitalizations for HF: TRILUMINATE Michael O'Riordan March 31, 2025
News Conference News ACC 2025 Evolut Low Risk Trial: TAVI Holds Up to Surgery at 5 Years L.A. McKeown March 30, 2025
News Conference News ACC 2025 Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI Caitlin E. Cox March 30, 2025
News Conference News ACC 2023 Stable CAD Plaque Morphology Improved by PCSK9 Inhibitors: YELLOW III Shelley Wood March 04, 2023
News Conference News ACC 2022 BIO|GUARD-MI: Post-MI Arrhythmia Monitoring Falls Short Todd Neale April 11, 2022
News Conference News ACC 2022 ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI Todd Neale April 05, 2022
News Conference News ACC 2021 Complete Revascularization Analysis of ISCHEMIA Opens ‘Pandora’s Box’ Michael O'Riordan May 18, 2021
News Conference News ACC 2021 Lancet Commission on CVD in Women Aims to Slash Global Burden Shelley Wood May 17, 2021
News Conference News ACC 2021 TALOS-AMI Supports Clopidogrel De-escalation After Earlier Ticagrelor Post-PCI Yael L. Maxwell May 17, 2021
News Conference News ACC 2020 Early Data Support TAVR in Bicuspid Valves, but Questions Remain Michael O'Riordan March 29, 2020
News Conference News ACC 2019 No TREAT for Ticagrelor at 12 Months: Fibrinolysis Patients After STEMI Do Just as Well on Clopidogrel Shelley Wood March 19, 2019
News Conference News ACC 2017 My Takeaways From ACC 2017: Even With a Sea Change, the Tide Takes Its Time Shelley Wood March 23, 2017
News Conference News ACC 2017 ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience Michael O'Riordan March 18, 2017
News Conference News ACC 2015 Coronary CTA Fails to Live Up to Its PROMISE in Suspected CAD L.A. McKeown March 14, 2015